Clinical trials: Mild Cognitive Impairment (MCI)
Alzheimer Disease, Mild Cognitive Impairment
Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia
This study is being performed to generate data regarding brain vibration /oscillation differences between individuals with dementia and normal controls.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Frontotemporal Lobar Degeneration, Memory Disorders
- Trial name
- NCT02333942
- Testing
- Nautilus NeuroWaveTM System
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Jan Medical, Inc.
Mild Cognitive Impairment
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.
- Trial name
- NCT05041790
- Testing
- Choline Alfoscerate
- Where
- South Korea
- Volunteers
- 418 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Alzheimer's Disease, Mild Cognitive Impairment
Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures
Alzheimer's disease (AD) clinically characterized by the cognitive impairment and lowering of various functional abilities lead to staggering costs and suffering, which are particularly related to the social impacts of caring for…
- Trial name
- DNS (NCT05153941)
- Where
- Greece
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Altoida
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment, Alzheimer's Disease
Comparison of PET Amyloid Imaging in Japanese and Western Subjects
This was a Phase 2, multicenter study to assess the extent and patterns of [18F] flutemetamol uptake in the brains of 3 groups of Japanese subjects: healthy volunteers (HV), amnestic mild cognitive impairment (aMCI), and probable…
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Healthy
- Trial name
- NCT02813070
- Testing
- [18F] Flutemetamol
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Mild Cognitive Impairment
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or…
- Trial name
- NCT04191486
- Testing
- T-817MA
- Where
- 37 sites in Czechia, Germany and 5 more
- Volunteers
- 221 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Alzheimer's Disease
A Study of SHR-1707 With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
This study aims to evaluate the safety, tolerability and pharmacodynamics of intravenous administration of SHR-1707 In patients with mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.
- Trial name
- NCT05681819
- Testing
- SHR-1707
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Alzheimer Disease, Chronic Traumatic Encephalopathy
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected…
- Trial name
- NCT06254469
- Testing
- [F-18]Flornaptitril
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- CereMark Pharma, LLC
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)
The purpose of this study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.
- Trial name
- NCT01421056
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 6 sites in United States, Italy
- Volunteers
- 74 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Alzheimer Disease, Mild Cognitive Impairment
Evaluating the Efficacy of Artificial Intelligence-based Computer Aided Diagnosis Software That Assists in Determining Whether or Not to Conduct Amyloid PET for the Diagnosis of Alzheimer's Disease by Predicting Amyloid PET Positivity in Mild Cognitive Impairment Patients
Purpose of clinical trial; This clinical trial is designed to evaluate the effectiveness of 'NeuroAI' prediction accuracy compared to the amyloid PET test results by retrospectively collecting medical data of patients with mild…
- Trial name
- NCT05383053
- Testing
- NeuroAI
- Where
- South Korea
- Volunteers
- 227 people
- Sponsor
- Neurozen Inc.
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Fall, Mild Cognitive Impairment (MCI)
Digital STEADI Efficacy
The aging of the U.S. population, combined with health care workforce shortages and insufficient access to effective fall prevention and exercise programs, has contributed to a high burden of fall-related injuries in older…
- Conditions
- Fall, Mild Cognitive Impairment (MCI), Aging
- Trial name
- NCT07852650
- Testing
- Digital STEADI-1, STEADI Standard of Care, Digital STEADI-2
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Friendi.fi Corporation
Alzheimer's Disease
Computer-Based Training for Mild Alzheimer's Disease
The primary objective of this study is to evaluate the effects of computer-based training program ("HiFi-AD") on the memory and cognitive abilities of individuals diagnosed with mild Alzheimer's Disease (AD).
- Trial name
- NCT00319891
- Testing
- Computer-based Cognitive Training
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Posit Science Corporation
Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI
Auditory Stimulation During Sleep to Enhance Long-Term Memory in Amnestic MCI
This study aims to evaluate the efficacy and safety of Elevvo AudiStim, a sleep auditory stimulation device, as a symptomatic treatment for patients with amnestic mild cognitive impairment (aMCI).
- Conditions
- Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI, Alzheimer or Mild Cognitive Impairment
- Trial name
- NCT07402590
- Testing
- Auditory Stimulation
- Where
- Spain
- Volunteers
- 37 people
- Sponsor
- Bitbrain
Alzheimer Disease, Dementia
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
The goal of this Phase 2 Alzheimer's study is to determine whether 1.0 mg/kg XPro1595 confers a benefit on cognition, function, and biomarkers of white matter and to further evaluate safety and tolerability.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- MINDFuL (NCT05318976)
- Testing
- XPro1595
- Where
- 41 sites in Australia, Canada and 6 more
- Volunteers
- 207 people
- Sponsor
- Inmune Bio, Inc.
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Cognition
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
The purpose is to compare solifenacin and oxybutynin with an inactive tablet and assess any potential effects on mental ability.
- Trial name
- SENIOR (NCT01126424)
- Testing
- Solifenacin, Oxybutynin
- Where
- 3 sites in United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Mild Cognitive Impairment
BestBrain Evaluation of Cognitive Memory & Executive-Function
This study is intended 1. To quantify the effects of the iRemember personalized EEG-NFB therapy on working memory and executive functions in subjects with MCI by calculating the percentage of change in the Neurotrax tests…
- Trial name
- BECOME (NCT03954340)
- Testing
- iRemember Neurofeedback (NFB)
- Where
- Israel
- Volunteers
- 140 people
- Sponsor
- BestBrain Ltd.
Age-related Functional Decline, Mild Cognitive Impairment
Health Benefits of Nutraceutical Supplementation in Older Adults.
This study examines a multi-ingredient nutraceutical designed to support several areas of health in older adults, including muscle strength, cognitive function, immune response, and inflammation.
- Trial name
- NCT07534878
- Testing
- Powder containing whey isolate and herbal extracts (30g sachet)
- Where
- India
- Volunteers
- 23 people
- Sponsor
- GPLIFE HEALTHCARE PRIVATE LIMITED